Nabriva Therapeutics plc (NASDAQ:NBRV) produced a 60.71% rally since recording the worst price of $1.12. Thanks to the latest 4.65% increase, it now trades at $1.8. Throughout the trading on 01/11/2019, the share price floated between $1.71 and $1.805. This company shares are 506.67% off its target price of $10.92 and the current market capitalization stands at $115.2M. The recent change has given its price a -4.91% deficit over SMA 50 and -74.06% deficit over its 52-week high. The stock witnessed -12.62% declines, -33.58% declines and -49.01% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NBRV’s volatility during a week at 6.11% and during a month it has been found around 11.06%.Nabriva Therapeutics plc (NBRV) Top Holders
Institutional investors currently hold around $57 million or 56.9% in NBRV stock. Look at its top three institutional owners. Vivo Capital, Llc owns $11.92 million in Nabriva Therapeutics plc, which represents roughly 10.34% of the company’s market cap and approximately 20.9% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 4,984,746 shares of the stock are valued at $8.97 million. The third largest holder is Novo Holdings A/S, which currently holds $8.47 million worth of this stock and that ownership represents nearly 7.35% of its market capitalization.
At the end of September reporting period, 29 institutional holders increased their position in Nabriva Therapeutics plc (NASDAQ:NBRV) by some 13,553,349 shares, 20 decreased positions by 2,744,346 and 5 held positions by 15,572,653. That puts total institutional holdings at 31,870,348 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 5,743,073 shares while 12 institutional investors sold out their entire positions totaling 2,572,163 shares.Nabriva Therapeutics plc (NASDAQ:NBRV) Insider Trades
Multiple company employees have indulged in significant insider trading. Nabriva Therapeutics plc disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Rowland Charles A Jr has acquired 53,000 shares of Nabriva Therapeutics plc (NBRV) in trading session dated Dec. 24, 2018. These shares are worth $69,430 and were traded at $1.31 each. The SEC filing shows that Burgess Daniel D performed a purchase of 36,000 shares. The Director added these shares by way of transaction on Jul. 31, 2018. The company’s shares were assimilated at $2.75 per share worth to an investment of some $99,000 on account of Burgess Daniel D.
Director, Talbot George Harrison, purchased 14,500 common shares of Nabriva Therapeutics plc (NBRV) in the open market. In a transaction dated Jul. 31, 2018, the shares were bought at an average price of $2.75, giving away a sum of $39,875. After this purchase, 47,640 common shares of NBRV are directly owned by the insider, with total stake valued at $85,752.
In the transaction dated Jun. 23, 2018, the great number of shares acquired came courtesy the Chief Scientific Officer; Gelone Steven P. added a total of 10,000 shares at an average price of $3.82, amounting to approximately $38,200. The insider now directly owns 22,740 shares worth $40,932.
Several analysts have released their opinion on Nabriva Therapeutics plc (NASDAQ:NBRV), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.